ExpreS2ion Biotechnologies

ExpreS2ion Biotechnologies is a clinical-stage biotechnology company headquartered in Denmark with a mission to develop innovative vaccines for a healthier world. They are focused on transforming healthcare by developing novel vaccines that are lifesaving and improve quality of life globally. Their approach leverages a proprietary protein expression system, ExpreS2, that utilizes insect cells to synthesize proteins essential for vaccine development. This platform is designed to accelerate drug candidate development with short timelines and cost-effective paths to value creation.

ExpreS2ion Biotechnologies has a robust pipeline of vaccine candidates, with their breast cancer vaccine being the most advanced. They also collaborate with Evaxion Biotech A/S on a cytomegalovirus vaccine using an AI-driven technology platform. In addition to their proprietary pipeline, they offer contract research organization (CRO) services to the biopharmaceutical industry and academia, utilizing their ExpreS2 platform to develop and produce hard-to-express proteins. ExpreS2ion Biotechnologies has demonstrated success in expressing over 500 proteins with a success rate exceeding 90%. They also sell ExpreS2 test kits and reagents for research purposes and diagnostic applications.

ExpreS2ion Biotechnologies' website does not explicitly state information about job flexibility, such as remote work or flexible hours.

ExpreS2ion Biotechnologies values its employees' diverse backgrounds and experiences, fostering a welcoming, respectful, and empowering culture. They encourage continuous learning and professional development, creating a collaborative environment that prioritizes innovation and creativity. The company's headquarters in Denmark is located in scenic surroundings at DTU Science Park, Hørsholm.

ExpreS2ion Biotechnologies is a clinical-stage biotechnology company dedicated to transforming healthcare by developing novel vaccines that are lifesaving and improve quality of life around the world. They leverage their proprietary ExpreS2 protein expression system, utilizing insect cells to synthesize proteins essential for vaccine development. This platform has been validated through Phase III clinical development and is being utilized to advance innovative therapies within oncology and infectious diseases, with a focus on accelerating the development of drug candidates with short timelines and cost-effective paths to value creation.

ExpreS2ion Biotechnologies promotes a culture of diversity, inclusivity, and continuous learning. The company values its employees’ unique experiences and backgrounds, fostering a collaborative environment that encourages innovation and creativity. With a focus on mutual respect and open communication, the company aims to create a positive and supportive atmosphere where employees feel welcomed, valued, and empowered to contribute to collective success.

ExpreS2ion Biotechnologies is committed to fostering a diverse and inclusive workplace, recognizing the value of different experiences and backgrounds. The company believes that a diverse team contributes to a better understanding of global customer needs, drives innovation, and enhances employee engagement. They actively seek to create a culture where everyone feels welcomed, valued, respected, and empowered to thrive.